logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

MNSO (09896) spent approximately HKD 16.907 million on September 4 to repurchase 890,400 shares.

date
18:22 04/09/2026
avatar
GMT Eight
MINISO (09896) announced that on September 4, 2026, it spent approximately HKD 16.907 million to repurchase 890,400 shares.
MNSO (09896) announced that on September 4, 2026, it spent approximately HKD 16.907 million to repurchase 890,400 shares.
Related Articles
China Stock
Beijing Balance Medical Technology Co., Ltd. (688198.SH): The registration application for the ophthalmic biological patch has not been approved.
New IPO News | Tongya Technology Plans Hong Kong Stock IPO, China Securities Regulatory Commission Requires Supplementary Explanation of Pricing Basis for Previous Capital Increases and Share Transfers
China Stock
Jiangsu Sihuan Bioengineering (000518.SZ) plans to acquire 65.6146% of Zhongrun Pharmaceutical for 160 million yuan.
Beijing Balance Medical Technology Co., Ltd. (688198.SH): The registration application for the ophthalmic biological patch has not been approved.
China Stock
New IPO News | Tongya Technology Plans Hong Kong Stock IPO, China Securities Regulatory Commission Requires Supplementary Explanation of Pricing Basis for Previous Capital Increases and Share Transfers
Jiangsu Sihuan Bioengineering (000518.SZ) plans to acquire 65.6146% of Zhongrun Pharmaceutical for 160 million yuan.
China Stock
RECOMMEND
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
icon
10/06/2026
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
icon
10/06/2026
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
icon
10/06/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.